Nuvo Research Inc. (NRI.TO), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, announced Thursday that a third party has received U.S. Food and Drug Administration or FDA approval to market and sell a topical diclofenac sodium 1.5% solution in the United States. The product is a generic version of Nuvo’s Pennsaid (diclofenac sodium topical solution) 1.5% w/w (Pennsaid 1.5%).